COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,544 Articles (22,881 medRxiv, 8,663 bioRxiv)

Most recent first Previous |  Page 2614: Articles 26131-26140  | Next

Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19
Mulgaonkar, N. S., Wang, H., Mallawarachchi, S., Ruzek, D., Martina, B., Fernando, S.
10.1101/2020.06.18.158196 — Posted: 2020-06-18
Polymorphism and selection pressure of SARS-CoV-2 vaccine and diagnostic antigens: implications for immune evasion and serologic diagnostic performance
Dumonteil, E., Herrera, C.
10.1101/2020.06.18.158329 — Posted: 2020-06-18
Early temporal dynamics of cellular responses to SARS-CoV-2
Banerjee, A., Budylowski, P., Richard, D., Maan, H., Aguiar, J., El-Sayes, N., D'Agostino, M. R., Tremblay, B. J.- M., Afkhami, S., Karimzadeh, M., Yip, L., Ostrowski, M. A., Hirota, J. A., Kozak, R., Capellini, T. D., Miller, M. S., McArthur, A. G., Wang, B., Doxey, A. C., Mubareka, S., Mossman, K.
10.1101/2020.06.18.158154 — Posted: 2020-06-18 Discussion: Onsite | Offsite
Cryo-EM structure of the SARS-CoV-2 3a ion channel in lipid nanodiscs
Kern, D. M., Sorum, B., Hoel, C. M., Sridharan, S., Remis, J. P., Toso, D. B., Brohawn, S. G.
10.1101/2020.06.17.156554 — Posted: 2020-06-18 Discussion: Onsite | Offsite
Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19
Oja, A. E., Saris, A., Ghandour, C. A., Kragten, N. A. M., Hogema, B. M., Nossent, E. J., Heunks, L. M. A., Cuvalay, S., Slot, E., Swaneveld, F. H., Vrielink, H., Rispens, T., van der Schoot, E., van Lier, R. A. W., Ten Brinke, A., Hombrink, P.
10.1101/2020.06.18.159202 — Posted: 2020-06-18 Discussion: Onsite | Offsite
Genomic surveillance of SARS-CoV-2 reveals community transmission of a major lineage during the early pandemic phase in Brazil
Resende, P. C., Delatorre, E., Graf, T., Mir, D., Motta, F. C., Appolinario, L., Paixao, A. C. D., Ogrzewalska, M., Caetano, B., Santos, M. C., Ferreira, J. A., Souza Junior, E. C., Silva, S. P., Fernandes, S. B., Vianna, L. A., Costa, L., Ferro, J., Nardy, V., Croda, J., Oliveira, W. K., Abreu, A. L. d., Bello, G., Siqueira, M. M.
10.1101/2020.06.17.158006 — Posted: 2020-06-18
Unexpected free fatty acid binding pocket in the cryo-EM structure of SARS-CoV-2 spike protein
Toelzer, C., Gupta, K., Yadav, S. K., Borucu, U., Garzoni, F., Staufer, O., Capin, J., Spatz, J., Fitzgerald, D., Berger, I., Schaffitzel, C.
10.1101/2020.06.18.158584 — Posted: 2020-06-18
The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins
Conceicao, C., Thakur, N., Human, S., Kelly, J. T., Logan, L., Bialy, D., Bhat, S., Stevenson-Leggett, P., Zagrajek, A., Hollinghurst, P., Varga, M., Tsirigoti, C., Hammond, J., Maier, H. J., Bickerton, E., Shelton, H. J., Dietrich, I., Graham, S. C., Bailey, D.
10.1101/2020.06.17.156471 — Posted: 2020-06-18
The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA
Cubuk, J., Alston, J. J., Incicco, J. J., Singh, S., Stuchell-Brereton, M. D., Ward, M. D., Zimmerman, M. I., Vithani, N., Griffith, D., Wagoner, J. A., Bowman, G. R., Hall, K. B., Soranno, A., Holehouse, A. S.
10.1101/2020.06.17.158121 — Posted: 2020-06-18 Discussion: Offsite
Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike
Ho, D. D., Lihong, L., Wang, P., Nair, M. S., Jian, Y., Huang, Y., Rapp, M. A., Wang, Q., Luo, Y., Sahi, V., Figueroa, A., Guo, X. V., Cerutti, G., Bimela, J., Gorman, J., Zhou, T., Kwong, P. D., G. Sodroski, J. G., Yin, M. T., Sheng, Z., Shapiro, L.
10.1101/2020.06.17.153486 — Posted: 2020-06-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).